Secukinumab: all 175 studies that test it

Page 1 of 2. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial SpondyloarthritisNot yet recruitingNCT07770646Phase 4
• Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular DiseaseNot yet recruitingNCT07704190Phase 4
• Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis SuppurativaRecruitingNCT07489573Phase 4
• Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu PatientsNot yet recruitingNCT07477795Phase 2
• Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingNCT07352566Phase 4
• IL-17 Blockade to Decrease irAEs (REPLAY)RecruitingNCT07237594Phase 1
• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingNCT07138898Phase 2
• Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing SpondylitisNot yet recruitingNCT06833112Phase 4
• Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).RecruitingNCT06751238Phase 1
• A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese PatientsRecruitingNCT06707246Not applicable
• Proactive TDM Versus Standard Use of Biologics in PsoriasisRecruitingNCT06398106Phase 4
• Immunoclassification of Psoriasis: a Strategy for Precision MedicineRecruitingNCT05503875Not applicable
• A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing SpondylitisRecruitingNCT05303285Phase 4
• Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic ArthritisRecruitingNCT04610476Phase 3
• Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque PsoriasisNot yet recruitingNCT04239859Phase 4
• Effects of Treatment With Biological Agents on Vascular and Cardiac Function in PsoriasisRecruitingNCT02144857Phase 4
• Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff TendinopathyTerminatedNCT05758415Phase 3Results posted
• Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff TendinopathyTerminatedNCT05722522Phase 3Results posted
• Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff TendinopathyCompletedNCT05569174Phase 3Results posted
• Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus NephritisTerminatedNCT05232864Phase 3Results posted
• A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)TerminatedNCT04737330Phase 3Results posted
• Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial SpondyloarthritisCompletedNCT04732117Phase 3Results posted
• Brain Changes in Psoriasis After Secukinumab TreatmentCompletedNCT04717466Phase 4Results posted
• Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.CompletedNCT04711902Phase 3Results posted
• Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor TreatmentCompletedNCT04632927Phase 3Results posted
• PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen PlanusCompletedNCT04300296Phase 2Results posted
• A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)TerminatedNCT04237116Phase 3Results posted
• Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic ArthritisCompletedNCT04209205Phase 3Results posted
• Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus NephritisTerminatedNCT04181762Phase 3Results posted
• Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis SuppurativaCompletedNCT04179175Phase 3Results posted
• Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpACompletedNCT04156620Phase 3Results posted
• Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)TerminatedNCT03791060Phase 2Results posted
• An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)CompletedNCT03769168Phase 3Results posted
• A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell ArteritisCompletedNCT03765788Phase 2Results posted
• Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)CompletedNCT03713632Phase 3Results posted
• This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).CompletedNCT03713619Phase 3Results posted
• Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque PsoriasisCompletedNCT03668613Phase 3Results posted
• Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT03589885Phase 3Results posted
• Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque PsoriasisCompletedNCT03504852Phase 3Results posted
• Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing SpondylitisCompletedNCT03350815Phase 4Results posted
• Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse TendinopathyCompletedNCT03344640Phase 2Results posted
• Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)CompletedNCT03259074Phase 3Results posted
• SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritisCompletedNCT03136861Phase 3Results posted
• Safety and Efficacy of Secukinumab in Mild PsoriasisCompletedNCT03131570Phase 2Results posted
• Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular RosaceaCompletedNCT03079531Phase 1/2Results posted
• Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type PsoriasisCompletedNCT03066609Phase 3Results posted
• Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis PatientsCompletedNCT03055494Phase 4Results posted
• The Efficacy and Safety of Secukinumab in Patients With IchthyosesCompletedNCT03041038Phase 2Results posted
• Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)CompletedNCT03031782Phase 3Results posted
• Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque PsoriasisCompletedNCT03020199Phase 4Results posted
• Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing SpondylitisCompletedNCT02896127Phase 3Results posted
• Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque PsoriasisCompletedNCT02826603Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to PlaceboCompletedNCT02798211Phase 4Results posted
• Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon SiteCompletedNCT02771210Phase 3Results posted
• Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing SpondylitisCompletedNCT02763046Phase 4Results posted
• A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.CompletedNCT02752776Phase 4Results posted
• Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing SpondylitisCompletedNCT02750592Phase 3Results posted
• Study of Secukinumab With 2 mL Pre-filled SyringesCompletedNCT02748863Phase 3Results posted
• Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic ArthritisCompletedNCT02745080Phase 3Results posted
• Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton InvolvementCompletedNCT02721966Phase 3Results posted
• Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial SpondyloarthritisCompletedNCT02696031Phase 3Results posted
• Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT02690701Phase 4Results posted
• Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)CompletedNCT02662985Phase 3Results posted
• A Study of Secukinumab for the Treatment of Alopecia AreataTerminatedNCT02599129Phase 2Results posted
• Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe PsoriasisCompletedNCT02595970Phase 3Results posted
• Secukinumab for Treatment of Atopic DermatitisCompletedNCT02594098Phase 2Results posted
• Immunologic Response to Secukinumab in Plaque PsoriasisCompletedNCT02592018Phase 4Results posted
• Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With SecukinumabCompletedNCT02559622Phase 3Results posted
• Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine ACompletedNCT02547714Phase 4Results posted
• Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.CompletedNCT02474082Phase 3Results posted
• Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type PsoriasisCompletedNCT02474069Phase 3Results posted
• Plaque Psoriasis Efficacy and Safety With SecukinumabCompletedNCT02409667Phase 3Results posted
• Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic ArthritisCompletedNCT02404350Phase 3Results posted
• A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)CompletedNCT02394561Phase 3Results posted
• Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional BiomarkersCompletedNCT02362789Phase 3Results posted
• 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic ArthritisCompletedNCT02294227Phase 3Results posted
• Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp PsoriasisCompletedNCT02267135Phase 3Results posted
• 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing SpondylitisCompletedNCT02159053Phase 3Results posted
• Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type PsoriasisCompletedNCT02074982Phase 3Results posted
• Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes MellitusTerminatedNCT02044848Phase 2Results posted
• 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis PatientsCompletedNCT02008916Phase 3Results posted
• Palmoplantar Pustular Psoriasis Efficacy and Safety With SecukinumabCompletedNCT02008890Phase 3Results posted
• 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic ArthritisCompletedNCT01989468Phase 3Results posted
• Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.CompletedNCT01961609Phase 3Results posted
• Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)CompletedNCT01952015Phase 3Results posted
• Extension Study up to 3 Years for Secukinumab in Psoriatic ArthritisCompletedNCT01892436Phase 3Results posted
• Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple SclerosisTerminatedNCT01874340Phase 2Results posted
• Extension in AS: Sustainability of Benefits, Safety and TolerabilityCompletedNCT01863732Phase 3Results posted
• Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail PsoriasisCompletedNCT01807520Phase 3Results posted
• Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar PsoriasisCompletedNCT01806597Phase 3Results posted
• Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.TerminatedNCT01770379Phase 3Results posted
• Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic ArthritisCompletedNCT01752634Phase 3Results posted
• 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing SpondylitisCompletedNCT01649375Phase 3Results posted
• 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type PsoriasisCompletedNCT01640951Phase 3Results posted
• Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)CompletedNCT01636687Phase 3Results posted
• First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 WeeksCompletedNCT01555125Phase 3Results posted
• Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With SecukinumabCompletedNCT01544595Phase 3Results posted
• Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis PatientsCompletedNCT01537432Phase 2Results posted
• Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled AsthmaTerminatedNCT01478360Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01433250Phase 2Results posted

← Secukinumab overview